×
The central $37 target is the arithmetic mean of three verifiable analyst price targets—$32, $35, and $44—reviewed for this article. The latest verified market price is $31.61 , so reaching $37 implies roughly a 17% upside, a substantial but not extreme move.
AZTA surged from its previous close of $40.48 to $47.74, a gain of +17.93%, during regular trading hours. The catalyst: Q4 FY2026 results released after the November 10 close beat estimates, with adjusted EPS of $0.28 versus a $0.11 consensus.
ICUI slipped -1.31% to $179.73 from a previous close of $182.11 during regular market hours. No verified news or fundamental catalyst found — with no company headlines today, the dip looks like mild profit-taking after a roughly +13% gain over the past month, and the move is smaller than the stock's ~1.6% typical daily swing.
ISRG (Intuitive Surgical) is a large-cap, profitable leader in robotic-assisted surgery, while PRCT (PROCEPT BioRobotics) is a smaller, high-growth but still loss-making player focused on urology. Both companies delivered solid revenue growth in recent quarters, but ISRG's scale and recurring-revenue model contrast sharply with PRCT's early-stage profitability and cash-burn profile.
Bionano Genomics (NASDAQ: BNGO) is scheduled to report third quarter 2026 results after the market close on November 10, 2026, with a conference call at 4:30 p.m. ET. Consensus revenue estimates stand at approximately $8.44 million, while the company previously guided Q3 2026 revenue to a range of $8.2 million to $8.6 million, up 11% to 16% year over year.
The central $5 target is the arithmetic mean of two verified analyst price targets: $4 from Maxim Group and $6 from H.C. Wainwright. With the stock near $1.16, reaching $5 would require a roughly 330% advance—a very large move by any standard.
The central target of $40 reflects the reverse-split-adjusted analyst price target; it is not a broad multi-analyst consensus, because coverage of NXGL is extremely thin. The most recently verified price of about $3.56 (late October 2026) implies a required upside of roughly 1,020% to reach $40 — a very large move that is heavily influenced by the 1-for-20 reverse split, which reduced shares outstanding from about 9.75 million to roughly 487,000.
The $13 central target is a fallback benchmark, not an analyst consensus; it reflects the highest current published target and the only objective meaningfully above the recent price near $9.25. Reaching $13 implies roughly 40% upside — a substantial move for a micro-cap turnaround.
NEXGEL is expected to report its third-quarter 2026 results around mid-November 2026, covering the period ended September 30, 2026. Wall Street consensus points to revenue of roughly $4.19 million , up about 43% from $2.93 million a year earlier, alongside a continued net loss per share.
Revenue rose 8% year over year to $22.2 million , marking a second straight quarter of solid top-line growth. Adjusted EPS (earnings per share) came in at -$0.06 , beating the consensus estimate of -$0.27, while revenue topped the $21.85 million estimate.
The central target is $3.10 , the arithmetic mean of four verified current analyst price targets, rounded from $3.125. At a recent price near $1.08 , reaching $3.10 would require a rise of roughly 185% — a very large move.
Stereotaxis is scheduled to report its third quarter 2026 results after the U.S. market close on Tuesday, November 10, 2026. Consensus estimates point to a net loss of roughly $0.05 per share on revenue near $9.6 million .
The central stock price target of $6.25 is the arithmetic mean of four current, verifiable analyst price targets, ranging from $5.00 to $8.00. With shares trading near $3.23 , reaching $6.25 would require a gain of roughly 94% , a very large move.
KORU Medical Systems (KRMD) reports third quarter 2026 results on Tuesday, November 10, after the market close, with a conference call at 4:30 p.m. ET. Wall Street consensus calls for a net loss of about $0.02 per share on revenue of roughly $11.33 million , up about 8.9% year over year.
The central target used here is $46 per share , about 12% above the latest close near $40.95. This target is not an analyst consensus . Published analyst price targets cluster between roughly $33 and $45 and average around $38, slightly below the current price, so $46 reflects a technical and psychological milestone near the 52-week high of $46.41.
Azenta is expected to report results for the fourth quarter of fiscal 2026 (the three months ended September 30, 2026) in late November 2026. Management has guided fourth-quarter organic revenue to decline in the low single digits year over year, weighed down by a tough comparison against the record fourth quarter of fiscal 2025.
The central target of $90 is the arithmetic mean of verified analyst price targets that sit above Alcon's current share price, not an official published consensus. With shares near $75.14, reaching $90 would require a rise of roughly 20%, a substantial move from current levels.
Alcon is scheduled to report its third-quarter 2026 results after the market close on November 10, 2026, with a conference call the following morning. Wall Street consensus calls for core EPS (earnings per share) of roughly $0.89 on revenue near $2.68–2.73 billion, up from $0.79 and $2.59 billion a year earlier.
The central target used here is $86 , calculated as the average of verified analyst price targets that sit above the latest market price of $75.14. That $86 figure is roughly 14% above the current price, requiring a substantial but not extreme advance.
Alcon Inc. (ALC) is scheduled to report its third-quarter 2026 results on Tuesday, November 10, 2026, after the market close, followed by a conference call on November 11. Wall Street consensus points to earnings per share (EPS) of roughly $0.89, compared with $0.79 in the prior-year quarter.